INNOVIVA, INC. Variable Lease, Cost
INNOVIVA, INC. (INVA) reported Variable Lease, Cost of $131.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:VariableLeaseCost · last filed 2026-08-05
- INNOVIVA, INC. variable lease, cost for the quarter ending 2026-06-30 was $131.00K, a 4266.67% increase year-over-year.
- INNOVIVA, INC. variable lease, cost for the quarter ending 2026-03-31 was $128.00K, a 6300.00% increase year-over-year.
- INNOVIVA, INC. variable lease, cost for the quarter ending 2025-06-30 was $3.00K, a 62.50% decline year-over-year.
- INNOVIVA, INC. variable lease, cost for the quarter ending 2025-03-31 was $2.00K, a 50.00% decline year-over-year.
- INNOVIVA, INC. variable lease, cost for fiscal 2025 was $91.00K, a 550.00% increase from fiscal 2024.
- INNOVIVA, INC. variable lease, cost for fiscal 2024 was $14.00K, a 92.59% decline from fiscal 2023.
- INNOVIVA, INC. variable lease, cost for fiscal 2023 was $189.00K, a 21.94% increase from fiscal 2022.
- INNOVIVA, INC. variable lease, cost for fiscal 2022 was $155.00K.
| Period end | Variable Lease, Cost 3 month | Variable Lease, Cost 6 month | Variable Lease, Cost 9 month | Variable Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $131.00K 10-Q · filed 2026-08-05 | $259.00K 10-Q · filed 2026-08-05 | ||
| 2026-03-31 | $128.00K 10-Q · filed 2026-05-06 | |||
| 2025-12-31 | $91.00K 10-K · filed 2026-02-25 | |||
| 2025-06-30 | $3.00K 10-Q · filed 2026-08-05 | $5.00K 10-Q · filed 2026-08-05 | ||
| 2025-03-31 | $2.00K 10-Q · filed 2026-05-06 | |||
| 2024-12-31 | $14.00K 10-K · filed 2026-02-25 | |||
| 2024-06-30 | $8.00K 10-Q · filed 2025-08-06 | $12.00K 10-Q · filed 2025-08-06 | $57.00K derived: sum of 3 quarters · filed 2026-02-25 | $106.00K derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $4.00K 10-Q · filed 2025-05-07 | $49.00K derived: sum of 2 quarters · filed 2026-02-25 | $98.00K derived: sum of 3 quarters · filed 2026-02-25 | $145.00K derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $45.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $94.00K derived: sum of 2 quarters · filed 2026-02-25 | $141.00K derived: sum of 3 quarters · filed 2026-02-25 | $189.00K 10-K · filed 2026-02-25 |
| 2023-09-30 | $49.00K 10-Q · filed 2023-11-01 | $96.00K derived: sum of 2 quarters · filed 2024-07-31 | $144.00K 10-Q · filed 2023-11-01 | $189.00K derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | $47.00K 10-Q · filed 2024-07-31 | $95.00K 10-Q · filed 2024-07-31 | $140.00K derived: sum of 3 quarters · filed 2025-02-26 | $175.00K derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | $48.00K 10-Q · filed 2024-05-08 | $93.00K derived: sum of 2 quarters · filed 2025-02-26 | $128.00K derived: sum of 3 quarters · filed 2025-02-26 | |
| 2022-12-31 | $45.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $80.00K derived: sum of 2 quarters · filed 2025-02-26 | $155.00K 10-K · filed 2025-02-26 | |
| 2022-09-30 | $35.00K 10-Q · filed 2023-11-01 | $110.00K 10-Q · filed 2023-11-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |